Tradestie Institutional Equity Comparison Engine
ACRS vs LYRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACRS Overall Edge
ACRS Captures Institutional Edge (3โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aclaris Therapeutics, Inc. (ACRS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ACRS trades at N/M Forward P/E with -1412.4% operating margin (-55.1% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, ACRS sits in BREAKDOWN (1st %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ACRS N/M vs LYRA N/M Fwd P/E
Growth & Margin Winner
ACRS
Op Margin -1412.4% vs -25032.0% ยท YoY -55.1% vs -87.2%
Momentum & Technical Winner
ACRS
1Y +32.7% vs -94.3% ยท 52W Pos 25% vs 1%
Options & Structure Winner
ACRS
BREAKDOWN (1st %ile IV) vs UNCLASSIFIED (N/A IV)
ACRS
NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.35
-7.21% 1D
Market Cap
$621.8M
1M Return
-3.88%
1Y Return
+32.74%
Forward P/E
N/M
Unified AI Score
44.7 / 100
HOLD
Tech 41.0
Fund 54.0
Flow 64.0
Mom 70.0
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ACRS +32.74%
LYRA -94.34%
Spread: +135.55 pp (ACRS Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ACRS Revenue | LYRA Revenue | ACRS Op. Margin | LYRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | -1378.3% | N/A | ACRS |
| FY2019 | $0M | N/A | -2627.3% | N/A | ACRS |
| FY2020 | $10M | N/A | -785.4% | N/A | ACRS |
| FY2021 | $10M | $0M | -1327.1% | -15303.5% | ACRS |
| FY2022 | $30M | $0M | -302.0% | -4131.0% | ACRS |
| FY2023 | $30M | $0M | -311.6% | -4308.1% | ACRS |
| FY2024 | $20M | $0M | -758.2% | -6280.8% | ACRS |
| FY2025 | $10M | $0M | -975.9% | -7794.5% | ACRS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACRS | LYRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $621.8M | $2.3M | Larger Scale | ACRS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -55.1% | -87.2% | Higher Growth | ACRS |
| Operating Margin (TTM) Profitability | -1412.4% | -25032.0% | Higher Margin | ACRS |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -55.5% | -404.5% | Higher ROE | ACRS |
| 52-Week Range Position Momentum | 25% ($2โ$7) | 1% ($0โ$38) | Stronger Trend | ACRS |
| Beta / 30D Volatility Risk Regime | 1.56ฮฒ ยท 74% Vol | 0.33ฮฒ ยท 248% Vol | Lower Realized Risk | ACRS |
| Unified Institutional Score Composite Signal | 44.7 / 100 (HOLD) | 52.2 / 100 (HOLD) | Higher Composite | LYRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ACRS vs LYRA Buy Guide
ACRS
BREAKDOWN
130d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
1st %ile
IV Regime
Compressed (<25th %ile)
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ACRS nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.